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Prevention of seroma following inguinal
lymph node dissection with prophylactic,
incisional, negative-pressure wound
therapy (SEROMA trial): study protocol for a
randomized controlled trial
Mads Gustaf Jørgensen1 , Navid Mohammadpour Toyserkani1,4, Nana Hyldig2, Annette Hougaard Chakera3,
Lisbet Rosenkrantz Hölmich3, Jørn Bo Thomsen1 and Jens Ahm Sørensen1*
Abstract
Background: Radical inguinal lymphadenectomy (ILND) for metastatic melanoma is associated with a high
complication rate. Seroma is often the first postoperative complication, followed by prolonged wound healing
sometimes requiring reoperation, infection, multiple outpatient visits and re-hospitalization. Prevention of seroma
may, therefore, lead to a reduction in many of the other complications.
Methods/design: The primary aim of this randomized study is to investigate whether fewer patients require
treatment for seroma by immediate prophylactic application of incisional, Negative-pressure Wound Therapy
(iNPWT) following ILND, compared to standard postoperative treatment. The secondary outcomes include surgical-
site infection, dehiscence, hematoma, length of hospitalization, quality of life, safety, long-term assessment of
lymphedema and non-inferiority oncological outcome. Data will be registered prospectively at check-ups after 7
and 14 days, 1 and 3 months and 2 years after inguinal lymphadenectomy using case report forms and
questionnaires and stored in a secure online database.
Discussion: To our knowledge, this trial is the first randomized study evaluating negative-pressure wound therapy
as a prophylactic intervention for complications following melanoma-related ILND. The results from this trial will
hopefully determine the efficacy and safety of prophylactic iNPWT treatment in prevention of the clinical relevant
short- and long-term postoperative complications following ILND and may provide an evidence base for the an
improved postoperative regimen.
Trial registration: ClinicalTrials.gov, ID: NCT03433937. Prospectively registered on 15 February 2018.
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Background
The incidence of malignant melanoma is rising. If malig-
nant melanoma spreads, it is most commonly to the re-
gional lymph nodes [1]. Inguinal or ilioinguinal lymph
node dissection (ILND) is an operative intervention,
where the lymphatic tissue and surrounding fat is re-
moved from the groin en bloc to try to prevent further
dissemination of the melanoma [2]. In case of verified or
suspected metastasis to the pelvis, lymph nodes inferior
to the internal iliac artery are also removed. However,
the procedure is associated with a significant morbidity
rate [3]. Studies have shown that up to 80% of patients
undergoing ILND experience major postoperative compli-
cations such as seroma, surgical site infection (SSI), wound
breakdown, hematoma and lymphedema [4]. Seroma is a
collection of serous fluid in the wound cavity, formed by in-
flammatory exudates in response to the acute phase of
wound healing following surgical trauma and/or by leaking
lymph vessels [5]. Postoperative seroma is seen in about
50% of patient undergoing ILND [4], and is, therefore, one
of the most frequently encountered complications. The ser-
ous fluid accumulation distends the wound cavity leading
to increased risk of SSI, prolonged wound healing and pos-
sibly leading to higher risk of lymphedema [3]. Patients suf-
fering from seroma and related wound complications often
require prolonged hospitalization and multiple outpatient
visits with associated high costs to the health system [6, 7].
Due to the high complication rate following ILND [8], there
is a need for new evidence-based strategies to reduce the
risk of complications.
Incisional Negative-pressure Wound Therapy (iNPWT)
is a mechanical treatment modality, which has been shown
to facilitate wound healing through vacuum-assisted
closure [9]. The vacuum package consists of a single-use,
battery-powered device and a dressing, which can be ap-
plied to the surgical field after the incision has been closed.
Biomechanical studies have shown that iNPWT treatment
leads to removal of interstitial fluid and increased blood
and lymph flow which may in turn decreases the risk of
seroma and lymphedema [10–12]. The risk of postopera-
tive seroma and SSI following other surgical procedures
has been shown to be halved by the prophylactic use of
iNPWT [13]. However, it remains to be investigated as to
whether the same technique can be used to reduce compli-
cations after ILND.
The aim of this study is to investigate the value of
iNPWT in reducing complications following ILND, when
applied to the surgical field immediately after macroscopic
complete removal of all malignancy [14, 15].
Methods/design
Study objective
The aim of this study is to investigate whether patients
undergoing ILND due to lymph node metastasis from
melanoma will benefit from prophylactic iNPWT
(Smith&Nephew). The primary aim is to evaluate
whether patients treated with iNPWT will experience
less seroma formation than patients treated with stand-
ard dressing, measured by the need of seroma aspira-
tions by skin puncture. The secondary aims are to
examine whether the use of iNPWT results in a reduc-
tion of other major complications, length of
hospitalization, and improved patient quality of life. The
safety of iNPWT in the oncological setting will be evalu-
ated by comparing the distribution of patients with re-
gional recurrence between groups.
Sample size
It is estimated that at least 55% of patients undergoing
ILND require intervention due to postoperative seroma [3],
and we hypothesize that NPWT will reduce the number of
patients needing seroma aspirations by 50%. A two-sided
sample size calculation with 0.8 power and significance
level of 0.05 reveals that we will have to include 100 pa-
tients. With an estimated dropout rate of 10%, we will need
a sample size of 110 patients with 55 patients in the treat-
ment and control groups, respectively. Sample size was
calculated using STATA, version 14.0 (StataCorp, College
Station, TX, USA) using the two-sample proportion test.
Trial design
The study is a prospective, randomized, open-labeled, mul-
ticenter trial with two parallel groups (Fig. 1). Patients who
have given informed consent to participate in the study will
be randomized via a computer randomization program to
either prophylactic iNPWT or a standard postoperative
dressing (Micropore™ tape, 3 M, Copenhagen, Denmark)
in a 1:1 allocation. If a patient requires bilateral ILND, both
sides will be randomized individually. Included patients
will initially be followed for 3 months for monitoring of the
early postoperative complications. Any complications, both
short-term complications, lymphedema and cancer recur-
rence will be dealt with at time of occurrence according to
institutional protocol and national guidelines [16]. At the
2-year follow-up, the patient’s lower limbs will be clinically
assessed for lymphedema using the International Society of
Lymphology consensus [17]. Local cancer recurrence in
the operated groin will be calculated by 2 years of
follow-up. Trial participants will not receive any compen-
sation or remuneration for their participation in the trial.
This study is reported in accordance with the Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) Checklist for clinical trial protocols (Additional
file 1) [18].
Research ethics approval and data management
The trial has been approved by The Regional Com-
mittees on Health Research Ethics (S-20170085) and
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registered with the Danish Data Protection Agency
(2008–58-0018).
All protocol-required information on each participant is
recorded in an electronic case report form, using the secure
online system REDCap [19] (https://www.project-redca-
p.org/). The entered data will be stored on a secure server
in the Region of Southern Denmark via Odense Patient
data Explorative Network (https://open.rsyd.dk).
Study setting
The study will be conducted at the Department of Plastic
and Reconstructive Surgery, Odense University Hospital,
Denmark, the Department of Plastic and Reconstructive
Surgery, Herlev Gentofte Hospital, Denmark and the
Department of Plastic and Reconstructive Surgery,
Roskilde Hospital, Denmark. Additional study centers
may be included depending on logistics and feasibility.
Eligibility criteria
Eligible patients will be recruited at undisturbed consul-
tations and patients will not be contacted about the
study prior to this appointment. Patients are recruited
either during their follow-up course after skin melanoma
treatment where a metastasis to the groin area can be
Fig. 1 Screening, treatment and follow-up algorithm. Overview of the trial process
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identified clinically, by ultrasonography or PET-CT scan
and a subsequent biopsy will confirm the diagnosis. The
patient may also present with metastatic disease in the
groin at initial consultation. ILND will only be offered, if
there is no evidence of disease elsewhere and all such
patients will be discussed at a multi-disciplinary team
meeting according to national guidelines. Completion
lymph node dissection for micrometastatic disease diag-
nosed with sentinel node biopsy is by 2018 no longer
performed routinely in Denmark [16].
At the study centers, melanoma patients aged 18 years
or older referred for ILND will be screened for trial
eligibility. Before enrollment, patients will receive oral
and written information about the study and a folder
explaining their legal rights. Patients will be excluded
from the study if they are suspected of having residual
tumor in the groin following ILND, have received previ-
ous groin irradiation or are suffering from dementia or
any psychiatric disorder making them incapable of in-
formed consent or adherence to follow-up. Furthermore,
patients unable to communicate in Danish or English
will be excluded from the study.
Interventions
The ILND is performed by surgical removal of all lymph
nodes and adipose tissue in the triangular region delin-
eated by the sartorius muscle, adductor longus muscle
and the inguinal ligament. At the end of the procedure,
one or two suction drains are placed from the surgical
cavity though the subcutis and skin distally or lateral
from the inguinal wound, and anchored using a 3.0
nylon suture. All patients receive prophylactic, intraven-
ous, perioperative antibiotic according to allergy and in-
stitutional protocol. The wound is then closed using an
absorbable 3.0 vicryl suture and a 4.0 nylon or monofila-
ment absorbable suture and covered with an iNPWT
dressing or Micropore™ tape, depending on treatment
arm. The suction drain(s) is placed in a manner, which
allows the iNPWT to cover the surgical field in all cases.
The iNPWT dressing will be used for a total of 14 days,
and the dressing will be changed on the seventh postop-
erative day. After removal of the iNPWT dressing,
Micropore™ dressing is then optionally used to cover the
scar for up to 3 months postoperatively for all patients.
Patients in the control arm receive standard postopera-
tive wound dressing consisting of optional Micropore™
dressing for up to 3 months. The drain(s) are to be re-
moved at the seventh postoperative day or when there is
a daily output of less than 20 mL per drain, whichever
occurs first.
Follow-up and data collection methods
Clinical follow-up data and short-term complications
will be analyzed from the day of surgery up until
3 months after surgery. Patients will be seen at clinical
visits at day 7 and 14, as well as 1 and 3 months postop-
eratively. Data will be collected prospectively at every
check-up and registered in a case report form, whether
or not an outcome has occurred since the last check-up.
For registration of events outside of scheduled follow-up
visits, patients receive a handout case report form and
are instructed to bring the form, when in contact with
any health practitioner. Daily drain output will be regis-
tered on a separate case report form until drain removal
by the department staff. Two years after allocation, pa-
tients will be invited for an additional check-up and ex-
amined for lymphedema occurrence and regional
recurrence.
In Denmark, stage III melanoma patients are enrolled
in a national follow-up program consisting of clinical
examination every third month for the first 2 years, and
every sixth months for 3 years. After 5 years of hospital
follow-up, a yearly visit with the general practitioner is
advised until 10 years after initial cancer treatment. In
addition, the patients undergo routine PET-CT scans
after 6, 12, 24 and 36 months.
Patients lost to follow-up will be contacted for out-
come registration and electronic medical records will be
reviewed to identify missing data (Table 1).
Outcomes
The primary outcome is the number of patients requir-
ing seroma aspiration. For this study, seroma is defined
as all clinical recognized and punctured seromas, which
have an aspirated volume of at least 30 mL.
Secondary outcomes include the:
 Cumulative volume of aspirated seromas measured
in milliliters after aspiration. Timeframe: registered
until 3 months after ILND
 Cumulative number of seroma aspirations fulfilling
above criteria. Timeframe: registered until 3 months
after ILND
 Surgical site infection, defined as groin infection
requiring antibiotic treatment. Timeframe: registered
until 3 months after ILND
 Days until the last suction drain(s) is removed.
Timeframe: maximum 7 days
 Cumulative volume of collected lymph fluid
accumulated in the suction drains measured in
milliliters. Timeframe: registered until last drain
removal
 Health-related quality of life, assessed using the
validated EQ-5D-5 L [20] questionnaire. Timeframe:
assessed on the day of surgery, after 3 month and at
the final check-up 2 years after ILND
 Wound dehiscence, defined as a wound edge
dehiscence that requires secondary suturing or
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Table 1 Participant timelines
aIncisional NPWT dressing is changed at day 7, and removed at day 14. Thereafter wounds are optionally covered with Micropore™ tape until 3 months postoperatively
bOptional use of Micropore™ tape is used for the control group until 3 months postoperatively
cDrains are removed at the seventh postoperative day or when there is a daily maximum of 20 mL in the drain, whichever occurs first
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NPWT treatment. Timeframe: registered until
3 months after ILND
 Necrosis of the wound, defined as the presence of
dead tissue, which require debridement on the
attending physician’s discretion. Timeframe:
registered until 3 months after ILND
 Hematoma, defined as an inguinal surgical cavity
filled by blood or clots, which require evacuation.
Timeframe: registered until 3 months after ILND
 Length of hospitalization, defined as the number of
days from ILND until discharge. Timeframe:
registered until 3 months after ILND
 Re-admission times, defined as the cumulative
number of days that patients are re-admitted to the
ward or have inpatient visits for reasons relating to
the surgical site. Timeframe: registered until
3 months after ILND
 Reoperation, defined as any adverse complication
(e.g., deep infection, hematoma, wound dehiscence,
necrosis, continuous lymph leakage) from the
inguinal wound, resulting in the patient undergoing
a re-operation with opening of the wound/scar
under general anesthesia or wound revision with
skin graft or NPWT. Timeframe: registered until
3 months after ILND
 Lymphedema, defined as a clinical stage 1 or more
on the International Society of Lymphology clinical
grading scale [17]. Timeframe: registered at the 2-
year check-up after ILND
 Lymphedema-related quality of life, assed using the
LYM-QOL questionnaire [21]. Timeframe: registered
at the 2-year check-up after ILND
 Regional recurrence of melanoma, defined as any
melanoma recurrence in the groin verified by
pathology. Timeframe: evaluated by the 2-year
check-up after ILND. However, any recurrence will
be treated surgically or oncologically according to
national guidelines at the time of occurrence
Contact information, demographic data and data re-
lated to excised lymph nodes will be collected prospect-
ively for all patients, including age, sex, smoking, alcohol
consumption, Body Mass Index (BMI), diabetes, total
number of lymph nodes removed, number of metastatic
lymph nodes, size and location of metastases in the
lymph nodes, number of lymph nodes with perinodal
tumor growth and if the procedure also involved dissec-
tion of iliac lymph nodes.
Statistical analysis
All analysis will be conducted on the intention-to-treat
principle using STATA (StataCorp, College Station, TX,
USA). Baseline variables are used to describe the
characteristics of the trial participants. Continuous vari-
ables are summarized as mean and standard deviation or
as median and interquartile range (25th to 75th percen-
tiles) if the distribution is asymmetrical. Categorical vari-
ables are summarized as numbers and percentages. The
categorical variables will be compared between groups
with chi-squared test or Fisher’s exact test depending on
the number of events. The continuous variables will be
compared between groups using an unpaired t test or
Mann-Whitney depending on data representation. A
two-sided P value of less than 0.05 will be considered
significant and reported with a 95% confidence interval
when applicable
The primary outcome is the proportion of patients
with at least one seroma aspiration and will be com-
pared between groups using chi-squared test or Fisher’s
exact test, depending on the number of events.
The secondary outcomes consist of categorical and
continuous variables. SSI, wound dehiscence, wound ne-
crosis, hematoma, reoperation, lymphedema and regional
recurrence will be sampled as categorical variables and
compared between groups. The cumulative volume and
number of seroma aspirations, volume of collected lymph
fluid, days until drain removal, quality of life scores, length
of hospitalization and re-admission times will be registered
as continuous variables and compared between groups.
Subgroup analyses of patients with iliac LND will be
conducted as removal of these more proximal and
deeper lymph nodes require extensive surgery beyond
the inguinal boundary. Patients requiring this additional
surgery may be at an increased risk of additional mor-
bidity such as lymphedema, and recurrence.
Discussion
The purpose of this trial is to evaluate the efficacy and onco-
logical safety of iNPWT for the prevention of the clinically
relevant morbidities after ILND. In addition, this study is an
advancement of trial methodology for assessment of postop-
erative outcomes after lymph node excisions. The study is
expected to generate valuable new information in the pos-
sible prevention of postoperative complications and improve
recovery following cancer treatment.
Lymph node dissection is associated with considerable
morbidity and selection of appropriate patients is of import-
ance. For melanoma patients with a low lymph-node-tumor
burden (micrometastases in sentinel nodes), the MSLT-II
trial showed no additional 3-year survival for complete dis-
section when compared to observation and delayed lymph
node dissection in case the patient later revealed regional
metastases [2]. While a long-term survival comparison is
still pending, complete dissection provides better regional
disease control and could be advocated for patients with a
greater tumor burden, and the general opinion is that
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patients with larger metastases should still undergo lymph
node dissection if no evidence of distant metastases. Patients
undergoing dissection of the groin lymph nodes are particu-
larly prone to postoperative morbidity and previous studies
have suggested conservative and minimally invasive ILND
protocols [22, 23] however, these have yet to achieve broad
acceptance due to the risk of compromising oncological
safety. In this study, the ILND procedure is performed ac-
cording to the national guidelines in Denmark, and, there-
fore, does not vary between study groups. Because iNPWT
may increase tissue vascularization, the device is only ap-
plied when all malignancy has been excised. Thus, it is pre-
sumed that there will be no difference in regional
recurrence between intervention and control groups. The
safety and tolerability of iNPWT for other indications has
been well established for many years. Reported discomforts
related to its use has been associated to bandage removal,
which is similar to the discomfort following regular postop-
erative dressing removal [13, 24]. This minor discomfort is,
however, insignificant compared to the potential benefit of
iNPWTapplication.
The outcomes investigated in this study were chosen
due to their relevance to clinical practice and postopera-
tive complications were defined as the need for treatment.
The primary outcome, seroma, is often the first sign of a
problematic wound-healing trail and prevention may,
therefore, in turn, prevent some of the frequent subse-
quent complications. During the planning of the study,
blinding and the use of a sham iNPWT device was consid-
ered, but not found feasible due to the nature of the inter-
vention, which exerts a vacuum on the wound. The study
will be conducted in accordance with the published proto-
col and positive, negative and inconclusive results on the
short-term complications will be published, when all pa-
tients have completed their 3-month follow-up visits. A
separate publication on the long-term lymphedema evalu-
ation and regional recurrence will be published, when all
patients have completed their 2-year follow-up. All publi-
cations derived from this study will adhere to the Vancou-
ver author convention.
Prevention of diseases can be more efficient than treat-
ment if the preventive intervention is more cost-effective-
ness than the treatment [25, 26]. In this study, a relatively
inexpensive device may prevent several outpatient and in-
patient appointments and treatment-related costs. The re-
sults from this trial will, therefore, elucidate the efficacy
and safety of prophylactic iNPWT treatment in prevention
of the major short- and long-term postoperative complica-
tions following ILND. Regardless of the outcome, this
study will benefit the patients by providing a solid founda-
tion for future research in the field of prophylactic wound
care treatment after lymph node dissection for cancer in
general, possibly also in other regions such as the axilla
and the neck.
Trial status
At the time of manuscript submission, the trial is not
yet actively enrolling participants.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 239 kb)
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